REDWOOD CITY, Calif., Dec. 5 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from four studies at the 31st Annual San Antonio Breast Cancer Symposium, taking place December 10-14, 2008, at the Henry B. Gonzalez Convention Center. Two of the studies analyze Oncotype DX(R), the company's multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit as well as the likelihood of recurrence for women with early-stage breast cancer.
Following are details for each embargoed session (all times are Central Standard Time):
-- Thursday, December 11, 2008, 4 p.m. - 4:15 p.m. Abstract #25 Oral presentation (General Session 2): "GRB7-dependent pathways are potential therapeutic targets in triple-negative breast cancer" Presenter: Joseph Sparano, M.D., Montefiore-Einstein Cancer Center, New York Location: Exhibit Hall D -- Friday, December 12, 2008, 7 a.m. - 9 a.m. Abstract #2066 Poster presentation (Poster Session II: Prognosis and Response Predictions: Biomarkers -- Methods): "Quantitative gene expression analysis using Oncotype DX in ductal carcinoma in situ that is adjacent to invasive ductal carcinoma" Presenter: Rick Baehner, M.D., Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco Location: Exhibit Hall B -- Friday, December 12, 2008, 5 p.m. - 7 p.m. Abstract #3049 Poster presentation (Poster Session III: Tumor Cell and Molecular Biology: Hormonal Factors and Receptors): "Associations between estrogen receptor (ER) Alpha expression levels and ER genotypes" Presenter: Daniel Hayes, M.D., University of Michigan Health Sys
|SOURCE Genomic Health, Inc.|
Copyright©2008 PR Newswire.
All rights reserved